- Home
- GLTO vs WLDS Comparison
GLTO vs WLDS Comparison
Compare GLTO & WLDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- WLDS
- Stock Information
- Founded
- GLTO 2011
- WLDS 2014
- Country
- GLTO Denmark
- WLDS Israel
- Employees
- GLTO N/A
- WLDS N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- WLDS Computer Communications Equipment
- Sector
- GLTO Health Care
- WLDS Telecommunications
- Exchange
- GLTO Nasdaq
- WLDS Nasdaq
- Market Cap
- GLTO 23.7M
- WLDS 19.7M
- IPO Year
- GLTO 2020
- WLDS 2022
- Fundamental
- Price
- GLTO $5.72
- WLDS $1.89
- Analyst Decision
- GLTO
- WLDS
- Analyst Count
- GLTO 0
- WLDS 0
- Target Price
- GLTO N/A
- WLDS N/A
- AVG Volume (30 Days)
- GLTO 767.1K
- WLDS 531.9K
- Earning Date
- GLTO 11-04-2025
- WLDS 12-09-2025
- Dividend Yield
- GLTO N/A
- WLDS N/A
- EPS Growth
- GLTO N/A
- WLDS N/A
- EPS
- GLTO N/A
- WLDS N/A
- Revenue
- GLTO N/A
- WLDS $422,000.00
- Revenue This Year
- GLTO N/A
- WLDS N/A
- Revenue Next Year
- GLTO N/A
- WLDS N/A
- P/E Ratio
- GLTO N/A
- WLDS N/A
- Revenue Growth
- GLTO N/A
- WLDS N/A
- 52 Week Low
- GLTO $2.01
- WLDS $1.00
- 52 Week High
- GLTO $31.70
- WLDS $11.92
- Technical
- Relative Strength Index (RSI)
- GLTO 42.06
- WLDS 32.04
- Support Level
- GLTO $7.02
- WLDS $2.51
- Resistance Level
- GLTO $7.64
- WLDS $2.69
- Average True Range (ATR)
- GLTO 0.58
- WLDS 0.28
- MACD
- GLTO -0.55
- WLDS -0.09
- Stochastic Oscillator
- GLTO 0.25
- WLDS 0.38
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About WLDS Wearable Devices Ltd.
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.